Objective:

To evaluate and compare reversal of memory loss in community patients treated with ATT, Leqembi or Kisunla.

Background:

Over 7 million Americans are living with Alzheimer's, with projections to nearly 13 million by 2050. 1 in 9 people aged 65 and older has Alzheimer's, with 74% being age 75 or older.  Lifetime risk for Alzheimer's at age 45 is 1 in 5 for women and 1 in 10 for men. 

Design/Methods:

We followed 136 mild AD and MCI patients while on Kisunla or Leqembi therapy, 111 were on Leqembi, 25 patients were on Kisunla.  Blood biomarkers, cognitive evaluations, blood biomarkers including MOCA, neuropsychological testing, MRI and amyloid PET scans obtained before the start of ATT and after 12 months of ATT infusion therapy.  All patients completed the therapy with exception of one patient who suffered a severe brain trauma due to an MVA.

Results:

 In the entire group of patients, 15.9% experienced significant worsening of memory loss, 67.1% had no significant progression of memory loss, and 17% experienced complete reversal of the memory loss.  All patients in the reversal and no worsening group had complete resolution of the amyloid plaque as shown by the negative amyloid PET scan at 12 months.  No significant ARIA-E and ARIA-H was noted in the cohort group.  Fasting regimens as well as various supplements were added to the treatment with ATT.  Kisunla group had a higher percentage of complete reversal of memory loss compared to Leqembi, however the Leqembi group included a significant higher number of patients.

Conclusions:

In this community cohort of patients, our study showed that the majority of the patients experienced no significant progression of AD and about a third even had complete resolution of the amyloid plaque deposition as well as perfect scores on memory loss re-evaluations at 12 months.